Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

Inclusion Criteria: * Clinical diagnosis of ocular hypertension, primary open-angle glaucoma or pigmentary glaucoma; * Intraocular pressure (IOP) of between 19 to 35 mmHg at any time of the day in at least one eye (designated as the study eye); * On a stable medication regimen for IOP reduction one week prior to the screening visit; * Best corrected visual acuity better than 20/200 (Snellen) or 1.0 (logMAR) in each eye; * Sign informed consent; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Known medical history of allergy, hypersensitivity or low tolerance to any of the components of DuoTrav®; * Any abnormality that would preclude the reliable performance of applanation tonometry in either eye; * Infection in either eye; * Conventional or laser intraocular surgery in either eye 3 months prior to screening visit; * Risk for visual field or visual acuity worsening, in the opinion of the investigator; * Women of childbearing potential; * Pregnant or lactating women; * Any condition that, in the opinion of the principal investigator, could interfere with participation in the study, or that could present a risk to the participant. * Participation in another clinical study within 30 days before the screening visit; * Other protocol-defined exclusion criteria may apply.